Pro Medicus (ASX:PME) Tests Its Valuation Narrative On Annual Results And Dividend

Pro Medicus (ASX:PME) is in focus after reporting full year 2026 earnings, with sales of A$261.69 million, revenue of A$270.75 million and net income of A$265.34 million, alongside announcing an ordinary dividend of A$0.37 per share.

See our latest analysis for Pro Medicus.

The latest earnings and dividend news for Pro Medicus comes after a sharp 49.75% 90 day share price return and a 10.46% 30 day share price gain, although the 1 year total shareholder return has fallen 37.23%. Recent momentum therefore follows a weaker longer term patch.

If you are considering other healthcare names with potential AI exposure, it could be a good time to scan the market using our screener of 7 healthcare AI stocks

After Pro Medicus stock surged over the past three months yet remains well below its 1 year high, the key issue now is balance. Do recent results and the current valuation still leave enough upside to justify the risk?

Most Popular Narrative: 2.6% Undervalued

According to the most widely followed narrative on Pro Medicus, a fair value of A$196.78 compares to the last close of A$191.60, which implies a modest valuation gap that recent share price swings have not fully closed.

At $120, the stock offers an asymmetric setup: you are not buying a distressed company, you are buying a best-in-class franchise that has temporarily disappointed quarterly expectations in a business where revenue is inherently lumpy. The contract backlog, the renewal rate, the margin profile, and the expanding addressable market have not changed. The price has.

Read the complete narrative.

Want to see what underpins that fair value for Pro Medicus? The narrative leans on sustained revenue expansion, strong profitability, and a rich earnings multiple that only works if those trends continue.

Result: Fair Value of A$196.78 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Pro Medicus also faces real pressure points, including any slowdown in imaging contract wins or sharper competition in enterprise imaging that could challenge this undervalued thesis.

Find out about the key risks to this Pro Medicus narrative.

Another View on Pro Medicus Valuation

While the leading narrative sees Pro Medicus as about 2.6% undervalued at a fair value of A$196.78, the simple earnings multiple tells a different story. The current P/E of 75.4x is far higher than the global Healthcare Services average of 29.2x and above peers at 35.1x. It also sits well above a fair ratio of 33.3x, which is the level the market could move towards. That kind of gap points to meaningful valuation risk if sentiment turns.

For investors weighing these mixed signals, the key question is whether Pro Medicus can justify such a premium for long enough to keep that gap from closing on the share price.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Pro Medicus clearly mixed, now is the time to look through the numbers yourself and decide where you stand. To weigh up both sides of the story, take a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Pro Medicus?

If you are weighing up Pro Medicus, it can also help to compare it with other stocks that match your style using focused Simply Wall St screeners.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com